Evidence map›Paper›PMID 39844118›Full record

ArticleBMC pediatrics2025

The effect of azithromycin treatment on respiratory morbidity in children with down syndrome.

Inbal Golan-Tripto, Omer Dor, Noga Arwas, Itai Hazan, Guy Hazan, Aviv Goldbart

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Inbal Golan-TriptoPediatric Pulmonary Unit, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University, Yitzhak Rager Ave, PO Box 151, Beer Sheva, 8410101, Israel. inbalgt@clalit.org.il.ORCID 0000-0001-6259-405X
Omer DorFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Noga ArwasPediatric Pulmonary Unit, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University, Yitzhak Rager Ave, PO Box 151, Beer Sheva, 8410101, Israel.ORCID 0000-0003-2782-642X
Itai HazanFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.ORCID 0000-0002-6064-6909
Guy HazanPediatric Pulmonary Unit, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University, Yitzhak Rager Ave, PO Box 151, Beer Sheva, 8410101, Israel.ORCID 0000-0002-7372-6262
Aviv GoldbartPediatric Pulmonary Unit, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University, Yitzhak Rager Ave, PO Box 151, Beer Sheva, 8410101, Israel.ORCID 0000-0002-7063-4653

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChildren with Down syndrome (DS) often experience recurrent and prolonged hospitalizations from respiratory infections. While Azithromycin has been increasingly used for lower-respiratory tract infections (LRTIs) in children, its potential benefits for DS patients are unexplored. This study evaluates the effect of chronic azithromycin treatment on respiratory morbidity in children with DS.

methodsIn this retrospective cohort study, we analyzed data from children with DS aged 0-6 years treated with Azithromycin for at least 6 weeks (10 mg/kg, thrice weekly). Respiratory morbidity indicators, such as primary care visits, medication consumption, emergency department visits, hospitalizations, and hospital length of stay (LOS), were assessed and compared six months before and after the Azithromycin treatment.

resultsTwenty-three episodes of Azithromycin treatment (≥ 6 weeks) in eighteen children with DS (mean age of 2.3 years, 78% males) during 2016-2023 were included. A significant reduction in mean respiratory LOS was observed (13.6 vs. 4.7 days, p = 0.05) when comparing pre to post-Azithromycin treatment. Other secondary respiratory outcomes showed no significant differences.

conclusionThe significant reduction in respiratory LOS suggests the potential benefits of Azithromycin in children with DS, and emphasizes the need for larger clinical trials to determine optimal use and long-term effects in this vulnerable population.

Indexed as

Anti-Bacterial AgentsAzithromycinDown SyndromeRespiratory Tract InfectionsChildChild, PreschoolFemaleHospitalizationHumansInfantInfant, NewbornLength of StayMaleRetrospective StudiesTreatment OutcomeAnti-Bacterial AgentsAzithromycinAzithromycinChildrenDown syndromeRespiratory infectionsRespiratory morbidity

Identifiers

PMID39844118
PMCPMC11753151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.